ABT · News · 20260814N
Partner Ecosystem Expansion
ABBOTT LABORATORIES · 2026-08-14 · Importance 31 · Surprise 42 · In source text
Abbott will sell Freenome’s SimpleScreen CRC blood-based colorectal cancer test in the United States. Freenome’s SimpleScreen Lung test received FDA breakthrough device designation for detecting early lung cancer in high-risk individuals. Both tests use DNA methylation patterns and artificial-intelligence algorithms, highlighting Freenome’s expanding role in blood-based cancer diagnostics and Abbott’s commercial-partner ecosystem.
Key facts
- The news highlighted a partnership between Abbott Laboratories and Google Health. source
- Louis H. Morrone, an executive at Abbott Laboratories, sold 5,850 shares of company stock for $642,505. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | The news highlighted a partnership between Abbott Laboratories and Google Health. |